CASIRIVIMAB AND IMDEVIMAB 300 MG / 2.5 ML — DIN 02516691
CASIRIVIMAB : 300 MG / 2.5 ML IMDEVIMAB : 300 MG / 2.5 ML · HOFFMANN-LA ROCHE LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: AUTHORIZATION BY INTERIM ORDER REVOKED
What is CASIRIVIMAB AND IMDEVIMAB?
CASIRIVIMAB AND IMDEVIMAB 300 MG / 2.5 ML contains CASIRIVIMAB : 300 MG / 2.5 ML IMDEVIMAB : 300 MG / 2.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02516691, held by HOFFMANN-LA ROCHE LIMITED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as authorization by interim order revoked, status dated 21-Jun-2024. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
Is there a generic Casirivimab And Imdevimab in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Casirivimab And Imdevimab — 2 DINs, of which 0 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| HOFFMANN-LA ROCHE LIMITED | 2 | 0 | CASIRIVIMAB AND IMDEVIMAB | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 300 MG / 2.5 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Casirivimab And Imdevimab |
|---|---|
| ATC code | J06BD07 |
| AHFS class | 08:18.24 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02516691 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2516691 |
| Brand name | CASIRIVIMAB AND IMDEVIMAB |
| Generic / active ingredient | CASIRIVIMAB : 300 MG / 2.5 ML IMDEVIMAB : 300 MG / 2.5 ML |
| Market authorization holder | HOFFMANN-LA ROCHE LIMITED |
| Health Canada schedule | Schedule D |
| ATC code | J06BD07 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J06BD |
| Current status | AUTHORIZATION BY INTERIM ORDER REVOKED |
| Status date | 21-Jun-2024 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CASIRIVIMAB AND IMDEVIMAB | 1332 MG / 11.1 ML | SOLUTION | HOFFMANN-LA ROCHE LIMITED | AUTHORIZATION BY INTERIM ORDER REVOKED | 02516705 |
2 · Same class — other molecules in ATC J06BD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Nirsevimab | BEYFORTUS | 2 | 2 | Yes |
| Palivizumab | SYNAGIS | 4 | 0 | Not in Canada |
| Casirivimab And Imdevimab | CASIRIVIMAB AND IMDEVIMAB | 2 | 0 | Not in Canada |
| Sipavibart | KAVIGALE | 1 | 0 | Not in Canada |
| Sotrovimab | SOTROVIMAB FOR INJECTION | 1 | 0 | Not in Canada |
| Tixagevimab And Cilgavimab | EVUSHELD | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J06B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J06BA | Immunoglobulins, Normal Human, For Extravasc. Adm · Immunoglobulins, Normal Human, For Intravasc. Adm. | 50 | 16 |
| J06BB | Anti-D (Rh) Immunoglobulin · Cytomegalovirus Immunoglobulin · Hepatitis B Immunoglobulin · Rabies Immunoglobulin · Tetanus Immunoglobulin · +1 more | 36 | 10 |
| J06B | Immunoglobulins | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is authorization by interim order revoked in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.